As prescriptions for semaglutide and tirzepatide surge nationwide, a growing body of research shows that medication alone rarely produces lasting weight loss. Precision Telemed and Monj Health are launching the Advanced Metabolic Program to address what clinicians have started calling the missing piece in GLP-1 care.
United States, 12th Jun 2026 – GLP-1 medications such as compounded semaglutide and tirzepatide have changed what is possible in weight loss care. For the first time in decades, patients are seeing reductions of 15 to 20 percent of body weight, with improvements in blood sugar, blood pressure, and cardiovascular markers that were once reserved for surgery.
There is, however, a quieter problem unfolding behind those headlines. Roughly half of patients stop GLP-1 therapy within twelve months, and most regain a significant portion of the weight they lost. A January 2026 systematic review in The BMJ, drawing on 37 studies and more than 9,000 adults, found that weight returns at a rate of about 0.4 kilograms per month after stopping medication. At that pace, the average patient is back at baseline within 1.5 to 2 years.
“GLP-1 therapy is one of the most powerful tools we have, but it was never designed to be the whole solution,” said a spokesperson for Precision Telemed, a Tampa-based telehealth provider specializing in compounded GLP-1, sermorelin, testosterone, and anti-aging programs. “What patients need around the medication is the part that most clinics have not solved. That is exactly what this partnership was built for.”
The Missing Piece in Metabolic Care
In May 2025, four of the largest organizations in the field, the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society, jointly released a clinical advisory on GLP-1 use. Their central finding was direct: most patients prescribed GLP-1s do not receive adequate nutritional counseling or behavioral support, and outcomes suffer as a result.
The advisory noted that pairing GLP-1 therapy with structured nutrition guidance produces greater weight loss, better adherence, and a higher likelihood of sustained results after discontinuation. Without that scaffolding, patients face a familiar pattern of muscle loss, nutritional gaps, and rapid regain once the prescription ends.
Precision Telemed and Monj Health designed the Advanced Metabolic Program to close that gap. The program layers behavioral science, nutrition education, and live cooking instruction on top of clinically managed GLP-1 protocols, creating a single coordinated experience instead of a prescription and a wish of good luck.
What the Program Includes
Patients enrolled in the Advanced Metabolic Program receive their compounded GLP-1 medication through Precision Telemed, the same clinical pathway the company has used since its founding. The new layer comes from Monj Health and includes live cooking classes that teach practical, protein-forward meals, a four-phase metabolic structure that moves from Reset through Nourish, Maintain, and Sustain, habit-building tools rooted in self-determination theory, and personalized coaching from clinicians who understand both pharmacology and food.
The model directly addresses the concerns raised in the GLP-1 nutrition advisory, including muscle preservation through adequate protein intake, management of gastrointestinal side effects, and the behavioral skills patients need to maintain results once the medication is reduced or discontinued.
“What we are doing with Precision Telemed is not a supplement or an add-on,” said Adam DeVito, founder and CEO of Monj Health. “It is the part of metabolic care that was always supposed to be there. Your medication works on your biology. Monj works on everything else.”
Why This Matters Now
GLP-1 use in the United States has roughly doubled in the past three years, with one in twelve adults reporting current or past use as of 2024. Demand continues to climb, and so does the cost of weight regain. The same Oxford-led BMJ review found that cardiometabolic risk factors, including blood pressure and lipid markers, reverse almost in parallel with the weight, meaning patients who regain are also losing the cardiovascular protection the medication provided.
The Advanced Metabolic Program is currently active across Precision Telemed semaglutide and tirzepatide treatment pages, with full enrollment details rolling out in the coming weeks. The partnership is the first of its kind in the compounded telehealth space, where the standard of care has typically stopped at the prescription itself.
About Precision Telemed
Precision Telemed is a Tampa, Florida based telehealth provider offering compounded semaglutide, compounded tirzepatide, microdose GLP-1 and GLP-1 GIP protocols, sermorelin, testosterone, and NAD therapies. The company operates a HIPAA compliant platform and is LegitScript certified. All medications are dispensed through State Board of Pharmacy licensed sterile compounding pharmacies and FDA licensed 503(b) outsourcing facilities.
About Monj Health
Monj Health is a digital food-is-medicine platform built around behavioral science, live culinary instruction, and game-inspired engagement. Founded by Adam DeVito, the former Executive Chef and Head of New Concept Development at Kraft Foods, Monj has become one of the most thoughtfully designed digital health platforms in the country, working with employers, health systems, and now telehealth partners to make healthy living simple, sustainable, and genuinely enjoyable.
Media Contact
Organization: Precision Telemed
Contact Person: Carlie Cannon
Website: https://precisiontelemed.com/
Email: Send Email
Address:Tampa, Florida
Country:United States
Release id:46031
The post GLP-1 Patients Regain Most of Their Lost Weight Within 2 Years . A Tampa Telehealth Provider Is Partnering With a Digital Health Platform to Change That. appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Master of Financial journalist was involved in the writing and production of this article.